Missing BAP1 gene associated with immunosuppressive molecules in uveal melanoma

Google+ Pinterest LinkedIn Tumblr +

Immunotherapies using immune checkpoint inhibitors (ICI) have dramatically improved cancer survival in the last decade, resulting in the Nobel Prize for Medicine in 2018.

Unfortunately, a significant number of cancer patients are refractory to ICI or relapse these treatments by developing resistance mechanisms. Metastatic uveal melanoma is one of the most refractory cancers treated with immunotherapies and why these cancer patients do not respond to these treatments are still unknown.

The study conducted by researchers from the University of Liverpool, UK, and University of Turku, Finland, using state-of-the-art technologies to phenotype human uveal melanoma tumours, sheds some light on the mechanisms behind resistance to immunotherapies.

“One of the most common genetic alterations that initiates the development of uveal melanoma occurs in a tumour suppressor gene called BAP1. This gene is found absent or mutated in almost 50% of all uveal melanoma patients and is associated with high-risk of metastasis development, in which immunotherapy will not work,” says the lead author of the study, Dr Carlos R. Figueiredo from the University of Turku, Finland.

The researchers found that uveal melanoma cells lacking the BAP1 protein activate specific mechanisms that are responsible for shutting down T lymphocytes, the most important immune cells that fight and kill cancer cells.

Most importantly, the researchers discovered which molecules are potentially responsible for this process in uveal melanoma. Strikingly, some of these molecules can be promptly targeted using existing drugs that are approved for the management of other diseases.

Therefore, these results build a foundation for a new era of combinatory treatments using immune checkpoint inhibitors against metastatic uveal melanoma. However, the researchers highlight that further clinical studies are needed to establish the efficacy of these combinatory treatments.


Paper: Carlos R Figueiredo, Helen Kalirai, Joseph J Sacco, Ricardo A Azevedo, Andrew Duckworth, Joseph R Slupsky, Judy M Coulson, Sarah E Coupland. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development. The Journal of Pathology, 2020; 250 (4): 420 DOI: 10.1002/path.5384

Source: University of Turku

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.